Susan Cohn is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
645 N Michigan Ave
Suite 900
Chicago, IL 606112826
Telephone
312-926-3693Registry record last updated 26 Jan 2012.
Clinical trials
- PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma
Sponsor: Children's Oncology Group
- Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- HEMA Biologics, LLCProgram year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
- ViiV Healthcare CompanyProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Penem Antibacterial100%Ertapenem100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1988–2017 per NIH RePORTER. The latest:
- ITM 2.0: Advancing Translational Science in Metropolitan Chicago
University of Chicago
FY2017$5,837,630UL1TR002389 - Mechanism of SPARC peptide FSEC inhibition of angiogenesis in neuroblastoma
University of Chicago
FY2014$195,525R21NS080120
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”